SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors debate the sustainability of its recent rally amidst broader semiconductor volatility and shifting AI infrastructure demand. While some community members highlight the potential of its custom ASIC and data-center growth, others remain cautious, citing concerns over high valuations and the stock's tendency to give back gains during periods of market uncertainty.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is currently trending as investors debate the potential for a short squeeze ahead of Q2 earnings, with the community closely tracking the company's revenue growth, convertible note financing, and upcoming GPU deployment milestones. While some retail participants express frustration over the lack of a confirmed earnings date and historical dilution concerns, others are actively accumulating shares, citing strong institutional interest and an aggressive outlook for AI infrastructure.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is currently a focal point for investors as they weigh strong AI cloud growth and the potential value unlocking from a proposed IPO of its Kunlunxin chip subsidiary against broader concerns over Chinese macroeconomic stability and regulatory risks. While some analysts and major funds view the stock as a deeply undervalued play on the Chinese AI ecosystem, the community remains divided, with active debates centered on whether the company's valuation can hold up amidst intense competition and shifting geopolitical sentiment.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending as investors weigh strong earnings against concerns over sluggish housing market demand and high interest rates. The community is actively debating the stock's valuation and long-term viability, with many divided between viewing current levels as a deep-value buying opportunity and fearing further downside due to broader economic headwinds.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is trending as investors cheer positive topline results from the Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, with many noting the drug met all primary endpoints. The community is actively discussing the stock's significant after-hours pop, recent analyst upgrades, and the company's strong cash position, fueling speculation about potential institutional accumulation.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital is facing significant backlash from the community, who are actively criticizing leadership over stagnant stock performance and persistent insider selling. Investors remain deeply divided, with some pointing to unproven AI/data center pivots as a potential catalyst while others highlight technical weakness and financial distress as reasons to avoid the stock.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is generating significant buzz as investors track an upcoming court verdict regarding a multibillion-dollar antitrust lawsuit against Google, with community sentiment split between bullish anticipation of a major cash injection and caution regarding potential appeals. Traders are also closely monitoring the stock's recent partnership with Apple for a new device leasing program, which is fueling debate over the firm's long-term growth trajectory in the competitive fintech and BNPL sector.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is facing intense volatility as institutional investors and the community weigh the company's strong institutional backing and NDAA-compliant battery technology against the broader market's recent selling pressure. While investors remain focused on upcoming earnings and potential defense-sector tailwinds, social media conversation is dominated by debates over whether the current price action reflects genuine fundamental concerns or deliberate manipulation by market makers.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing significant market volatility, with the community actively debating whether the current price action signals a major buying opportunity or further downside risk. Discussions are heavily focused on network performance, staking dynamics, and potential supply shocks, while traders closely monitor its correlation with broader altcoin market trends.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is hitting multi-year lows amidst intense market skepticism and ongoing debates regarding its strategic direction and brand relevance. Investors are sharply divided, with some betting on a deep-value turnaround supported by the dividend, while others argue the stock faces further downside as it struggles to regain market momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 4, 2026 Registrational OptimUM-02 trial of the darovasertib...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., July 31, 2026 SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA...

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor...

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs

IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs PR Newswire SOUTH SAN FRANCISCO, Calif., July 17, 2026 SOUTH SAN FRANCISCO, Calif., July 17, 2026...

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif., June 26, 2026 SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ --IDEAYA...

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers

IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a...

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SOUTH SAN FRANCISCO, Calif., June 10, 2026...

Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures higher, Nasdaq up 200 points. Mission Produce (NASDAQ: AVO) shares down on weak earnings. Other stocks also down in pre-market.read more...

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants

IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO, Calif., June 8, 2026 SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA...

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire SOUTH SAN FRANCISCO, Calif., June 8, 2026 SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences...

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Nasdaq, S&P 500 Futures Slip As Hormuz Blockade Escalates Tensions: Why BATL, INTC, PLTR, IDYA Are On Traders' Radar Today

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$36.54
Prev Close	$36.30
Open	$36.04
Dividend Yield	0.00%
50-Day Moving Average	$35.11
Beta	1.19
Avg. Volume	944,603.19
PE Ratio	-18.81

52-Week High	$40.58
52-Week Low	$23.23
Market Capitalization	$3.5B
EPS (Annual)	-$1.28
Price to Book	2.94
Revenue Per Employee	$1.51M

Feed

News

Sentiment

Earnings

Fundamentals

Info